Antonio De Vita

Dr. Antonio De Vita

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 January 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
AVAntonio De Vita
Antonio De Vita
ABAntonietta Belmusto
Antonietta Belmusto
FPFederico Di Perna
Federico Di Perna
STSaverio Tremamunno
Saverio Tremamunno
GMGiuseppe De Matteis
Giuseppe De Matteis
Marcello CovinoMarcello Covino
Marcello Covino
Climate change is widely recognized as one of the most significant challenges facing our planet and human civilization. Human activities such as the burning of fossil fuels, deforestation, and industrial processes release greenhouse gases into the atmosphere, leading to a warming of the Earth’s climate. The relationship between climate change and cardiovascular (CV) health, mediated by air pollution and increased ambient temperatures, is complex and very heterogeneous. The main mechanisms underlying the pathogenesis of CV disease at extreme temperatures involve several regulatory pathways, including temperature-sympathetic reactivity, the cold-activated renin-angiotensin system, dehydration, extreme temperature-induced electrolyte imbalances, and heat stroke-induced systemic inflammatory responses. The interplay of these mechanisms may vary based on individual factors, environmental conditions, and an overall health background. The net outcome is a significant increase in CV mortality and a higher incidence of hypertension, type II diabetes mellitus, acute myocardial infarction (AMI), heart failure, and cardiac arrhythmias. Patients with pre-existing CV disorders may be more vulnerable to the effects of global warming and extreme temperatures. There is an urgent need for a comprehensive intervention that spans from the individual level to a systemic or global approach to effectively address this existential problem. Future programs aimed at reducing CV and environmental burdens should require cross-disciplinary collaboration involving physicians, researchers, public health workers, political scientists, legislators, and national leaders to mitigate the effects of climate change.

1 February 2021 in Atherosclerosis
Verified
Journal Article
Closed access
RMRocco Antonio Montone
Rocco Antonio Montone
MMmaria chiara meucci
maria chiara meucci
AVAntonio De Vita
Antonio De Vita
GLGaetano Antonio Lanza
Gaetano Antonio Lanza
GNGiampaolo Niccoli
Giampaolo Niccoli

29 March 2019 in Clinical Research in Cardiology
Verified
Journal Article
Closed access
PDF file
AVAntonio De Vita
Antonio De Vita
LMLaura Manfredonia
Laura Manfredonia
PLPriscilla Lamendola
Priscilla Lamendola
AVAngelo Villano
Angelo Villano
SRSalvatore Emanuele Ravenna
Salvatore Emanuele Ravenna
FCFilippo Crea
Filippo Crea

1 October 2022 in Trends in Cardiovascular Medicine
Verified
Journal Article
Closed access
GLGaetano Antonio Lanza
Gaetano Antonio Lanza
DMDoralisa Morrone
Doralisa Morrone
CPCarmine Pizzi
Carmine Pizzi
ITIsabella Tritto
Isabella Tritto
LBLuca Bergamaschi
Luca Bergamaschi
FCFilippo Crea
Filippo Crea

Verified
Journal Article
Open access
PDF file
ADAlessia d'Aiello
Alessia d'Aiello
ABAlice Bonanni
Alice Bonanni
RVRamona Vinci
Ramona Vinci
DPDaniela Pedicino
Daniela Pedicino
ASAnna Severino
Anna Severino
GLGiovanna Liuzzo
Giovanna Liuzzo
Type 2 diabetes mellitus (DM) represents, with its macro and microvascular complications, one of the most critical healthcare issues for the next decades. Remarkably, in the context of regulatory approval trials, sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1 RAs) proved a reduced incidence of major adverse cardiovascular events (MACEs), i.e., cardiovascular death and heart failure (HF) hospitalizations. The cardioprotective abilities of these new anti-diabetic drugs seem to run beyond mere glycemic control, and a growing body of evidence disclosed a wide range of pleiotropic effects. The connection between diabetes and meta-inflammation seems to be the key to understanding how to knock down residual cardiovascular risk, especially in this high-risk population. The aim of this review is to explore the link between meta-inflammation and diabetes, the role of newer glucose-lowering medications in this field, and the possible connection with their unexpected cardiovascular benefits.

12 November 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
AVAntonio De Vita
Antonio De Vita
SRSalvatore Emanuele Ravenna
Salvatore Emanuele Ravenna
Marcello CovinoMarcello Covino
Marcello Covino
OLOreste Lanza
Oreste Lanza
FFFrancesco Franceschi
Francesco Franceschi
GLGaetano Antonio Lanza
Gaetano Antonio Lanza
Background. Cardiac involvement in coronavirus SARS-CoV-2 infection (COVID-19) has been reported in a sizeable proportion of patients and associated with a negative outcome; furthermore, a pre-existing heart disease is associated with increased mortality in these patients. In this prospective single-center case-control study we investigated whether COVID-19 patients present different rates and clinical implications of an abnormal electrocardiogram (ECG) compared to patients with an acute infectious respiratory disease (AIRD) caused by other pathogens. Methods. We studied 556 consecutive patients admitted to the emergency department of our hospital with symptoms of AIRD; 324 were diagnosed to have COVID-19 and 232 other causes of AIRD (no-COVID-19 group). Standard 12-lead ECG performed on admission was assessed for various kinds of abnormalities, including ST segment/T wave changes, atrial fibrillation, ventricular arrhythmias, and intraventricular conduction disorders. Results. ECG abnormalities were found in 120 (37.0%) and 101 (43.5%) COVID-19 and no-COVID-19 groups, respectively (p = 0.13). No differences in ECG abnormalities were found between the 2 groups after adjustment for clinical and laboratory variables. During a follow-up of 45 ± 16 days, 51 deaths (15.7%) occurred in the COVID-19 and 30 (12.9%) in the no-COVID-19 groups (p = 0.39). ST segment depression ≥ 0.5 mm (p = 0.016), QRS duration (p = 0.016) and presence of any ECG abnormality (p = 0.027) were independently associated with mortality at multivariable Cox regression analysis. Conclusion. Among patients hospitalized because of AIRD, we found no significant differences in abnormal ECG findings between COVID-19 vs. no-COVID-19 patients. The ECG on admission was helpful to identify patients with increased risk of death in both groups of patients.